Alzheimer’s disease is a progressive brain disorder and the most common cause of dementia, gradually affecting memory, thinking, and the ability to manage everyday tasks. It develops slowly, often over many years, and it looks different at each stage. Doctors understand the condition far better than they did a decade ago, and new blood tests are starting to change how early it can be identified. This article explains what Alzheimer’s disease is, its early and later symptoms, the stages it moves through, the causes and risk factors behind it, how it is diagnosed today, the treatments now available, and how to support someone who is living with it.
What Alzheimer’s disease is
Alzheimer’s disease is a neurodegenerative condition, which means it slowly damages and destroys brain cells called neurons. As these cells stop working and die, the brain gradually shrinks and the networks that store memories and guide reasoning break down. Two abnormal proteins sit at the center of this process: beta-amyloid, which clusters into sticky plaques between neurons, and tau, which twists into tangles inside them. These silent changes can begin ten to twenty years before the first noticeable symptoms appear.
The disease is the leading cause of dementia, accounting for an estimated 60 to 80 percent of cases, according to the Centers for Disease Control and Prevention. Dementia itself is not one illness but a broad term for a decline in memory and thinking severe enough to interfere with daily life. Because several conditions can cause that decline, it helps to read our dementia symptoms and types guide. Seeing that wider category makes it clearer where Alzheimer’s fits.
How it differs from normal aging
Occasional forgetfulness is a normal part of getting older. The memory changes of Alzheimer’s are different: they are persistent, they steadily worsen, and they begin to disrupt familiar routines. The table below contrasts changes that may be early warning signs with the ordinary lapses many people notice as the years pass.
| Possible early sign of Alzheimer’s | More typical of normal aging |
|---|---|
| Forgetting recently learned facts or important dates and asking for the same information again and again | Sometimes forgetting a name or an appointment, then remembering it later |
| Struggling to follow a familiar recipe or to keep track of monthly bills | Occasionally needing help to use a phone setting or a new device |
| Getting lost on a well-known route or losing track of where you are | Briefly forgetting which day it is, then working it out |
| Repeatedly putting objects in unusual places and being unable to retrace your steps | Misplacing keys or glasses from time to time |
| Pulling away from work, hobbies, or friends, alongside marked mood changes | Feeling weary of routines or obligations now and then |
Symptoms: from early signs to later changes
Alzheimer’s symptoms usually appear gradually and grow more pronounced as the disease advances. Spotting the earliest signs matters, because an earlier assessment opens the door to support, planning, and, for some people, treatments that work best when they are started early.
Early signs
The first and most common symptom is memory loss that affects daily life, especially trouble holding on to newly learned information. Other early signs are easy to dismiss at first but tend to cluster together:
- Repeating questions or conversations and leaning more heavily on notes and reminders
- Difficulty finding the right word or following a discussion
- Losing track of dates, seasons, or the passage of time
- Trouble planning, solving simple problems, or handling money
- Misplacing items and being unable to retrace the steps taken
- Growing hesitation, anxiety, or withdrawal from usual activities
As the disease advances
Over time, memory gaps widen and other abilities are affected. A person may become confused about where they are or what year it is, struggle to recognize family and friends, and need help with dressing, bathing, and eating. Language becomes harder, judgment declines, and sleep patterns often shift. Changes in mood and behavior, such as suspicion, agitation, or restlessness, are common and can be distressing for families. In the most advanced stage, people lose the ability to hold a conversation, move around, and care for themselves, and they depend on others around the clock.
The stages of Alzheimer’s disease
Clinicians often describe Alzheimer’s as moving through broad stages. The pace varies widely from person to person, and the boundaries between stages are not sharp, but the framework helps families anticipate needs and plan care. The table below summarizes what each stage tends to look like.
| Etapa | What it often looks like |
|---|---|
| Preclinical (no symptoms) | Brain changes may be under way years before any symptoms, detectable only through research tests or biomarkers |
| Early (mild) | Memory lapses, word-finding trouble, and misplaced items; the person is usually still largely independent |
| Middle (moderate) | Greater confusion and difficulty with daily tasks; help is needed with dressing and meals, and behavior may change |
| Late (severe) | Loss of the ability to converse, walk, or manage personal care; full-time support is required |
Many specialists now add an earlier label, mild cognitive impairment, for thinking changes that are greater than normal aging but not yet severe enough to be called dementia. Not everyone with mild cognitive impairment goes on to develop Alzheimer’s, but it is an important window for assessment.
Causas y factores de riesgo
Alzheimer’s disease does not have a single cause. Most cases arise from a mix of aging, genetics, and health and lifestyle factors that build up over decades. Understanding these risks is useful because several of them can be influenced.
Age and genetics
Age is by far the strongest risk factor, and most people with Alzheimer’s are 65 or older. Genetics also play a part. A common gene variant called APOE e4 raises the risk, though carrying it does not guarantee the disease, and many people who develop Alzheimer’s do not carry it at all. A small number of families carry rare inherited mutations that cause early-onset Alzheimer’s, sometimes striking in a person’s forties or fifties. Family history and, in women, a slightly higher lifetime risk also contribute.
Heart health and lifestyle
What is good for the heart tends to be good for the brain. High blood pressure, diabetes, obesity, smoking, physical inactivity, hearing loss, and poor sleep are all linked to higher risk. Chronic inflammation may also play a role, and doctors sometimes review a CRP inflammation blood marker. B-vitamin balance matters too, a pattern often tied to low folate or vitamin B12, and our library explains elevated homocysteine levels and cognitive risks. None of these factors act alone, but together they help explain why brain health and body health are so closely connected.
How Alzheimer’s disease is diagnosed today
There is no single test that confirms Alzheimer’s in a doctor’s office. Instead, clinicians build a picture from several sources, and the tools available have improved dramatically in recent years.
Clinical assessment and cognitive testing
Diagnosis starts with a careful history, often with input from a family member, and a physical and neurological examination. Short cognitive tests measure memory, attention, language, and problem-solving. These pen-and-paper checks cannot diagnose the disease on their own, but they show whether thinking has changed and how much.
Brain imaging and spinal fluid
Brain scans help rule out other problems, such as a stroke or a tumor, and can reveal shrinkage in memory regions. Specialized PET scans can show amyloid or tau build-up directly, and a sample of spinal fluid can measure the same proteins. Both approaches are accurate but costly, invasive, or not widely available.
Blood biomarkers: a turning point
The biggest recent shift is the arrival of blood tests that detect Alzheimer’s biological changes. These measure a tau fragment called p-tau217, sometimes combined with the ratio of two amyloid proteins, and they flag the disease’s hallmark changes with an accuracy that approaches spinal fluid and PET testing. For a plain-language walkthrough, our team examined the p-tau217 blood test. In 2025, United States regulators cleared the first such test for clinical use, and our medical news desk explained the new FDA-cleared Alzheimer’s blood test. These tests are intended for people who already have symptoms, not for screening healthy adults, and they support rather than replace a full evaluation.
Ruling out conditions that mimic Alzheimer’s
Some memory problems come from treatable conditions rather than Alzheimer’s, so a good workup looks for reversible causes first. An underactive thyroid is a classic example, and doctors frequently check the TSH thyroid hormone test. Nutritional gaps matter too, because both can cloud thinking: our library describes low vitamin B12 symptoms and causes, and it also covers folate deficiency symptoms and causes. Mood is another key check, because low mood in older adults can look like memory loss, and our overview reviews depression symptoms, causes, and treatments. Correcting these issues can improve or even resolve the symptoms.
Treatments and day-to-day management
There is no cure for Alzheimer’s disease yet, but several treatments can help, and the options are broader than they were only a few years ago. Care usually combines medicines with practical support for the person and their family.
Medicines for symptoms
Two established families of drugs, cholinesterase inhibitors and memantine, do not stop the disease but can ease some symptoms and support daily function for a time. Doctors may also treat sleep problems, anxiety, or depression, which can make thinking and quality of life noticeably worse if left unaddressed.
Anti-amyloid antibody drugs
A newer class of treatment targets the disease itself. Lecanemab (sold as Leqembi) and donanemab (sold as Kisunla) are lab-made antibodies that clear amyloid from the brain and modestly slow the decline in early Alzheimer’s. Both have won United States approval; in 2023 the agency announced the traditional approval of lecanemab, and donanemab followed in 2024. The benefit is real but limited, the drugs are given by infusion, and they carry risks, including temporary brain swelling or small bleeds seen on scans, so they suit only carefully selected patients under close monitoring.
Everyday care and support
Beyond medicine, structure and routine help enormously. Simple calendars and reminders, a safe and familiar home, regular physical activity, social contact, and support for caregivers all improve daily life. Planning ahead for legal, financial, and care decisions while the person can still take part is one of the most valuable steps a family can take.
Reducing your risk and living well with the disease
There is no guaranteed way to prevent Alzheimer’s, but the same habits that protect the heart appear to protect the brain. Managing blood pressure and blood sugar, staying physically and mentally active, protecting hearing and sleep, not smoking, and keeping social ties may all help. The Centers for Disease Control and Prevention notes that a large share of dementia cases, close to half, may be prevented or delayed by addressing modifiable risk factors across a lifetime. For people already living with a diagnosis, meaning and connection remain possible, especially with early support, honest conversations, and a plan that adapts as needs change.
Avances científicos recientes
Research on Alzheimer’s disease is moving quickly, and two areas stand out. These findings are recent and still evolving, so they are best seen as important progress rather than the final word.
The first advance is the blood test. Scientists have shown that measuring p-tau217 (a fragment of the tau protein) in a simple blood sample, sometimes together with the amyloid 42-to-40 ratio, can identify the disease’s underlying biology about as reliably as a spinal tap or a brain PET scan, which is an imaging test that reveals protein build-up. A large study across ordinary doctors’ offices and memory clinics found that the blood test matched the true biology far more often than a physician’s first impression did. In 2025, the Alzheimer’s Association published its first clinical guideline supporting these blood tests in specialist settings. What this means for you: a straightforward blood draw may increasingly confirm or rule out Alzheimer’s as the source of memory symptoms, sparing more invasive tests, though for now the tests are meant for people who already have symptoms rather than for screening healthy people.
The second advance is treatment. Two lab-made antibodies (monoclonal antibodies, which are man-made proteins designed to stick to one specific target) have been developed to remove amyloid from the brain. In large trials known as CLARITY-AD for lecanemab and TRAILBLAZER-ALZ 2 for donanemab, both slowed the decline in thinking and memory in early Alzheimer’s, and both are now approved in the United States. What this means for you: for the first time, a treatment can slow the disease a little rather than only softening symptoms. The effect is modest, the drugs require infusions and careful monitoring, and they can cause side effects such as brain swelling or small bleeds, so doctors weigh the benefits and risks case by case. Taken together, earlier detection through blood tests and treatments that can act early point in the same encouraging direction, even as the science continues to develop.
Glosario
| Término | Definición |
|---|---|
| Alzheimer | The most common cause of dementia; a progressive brain disease that slowly damages memory and thinking. |
| Demencia | An umbrella term for a decline in memory and thinking severe enough to interfere with daily life. |
| Beta-amyloid | A protein that clumps into plaques between brain cells and is a hallmark of Alzheimer’s. |
| Tau (p-tau217) | A protein that forms tangles inside brain cells; its p-tau217 form can now be measured in blood. |
| Biomarcador | A measurable biological signal, in blood, spinal fluid, or on a scan, that reflects a disease process. |
| APOE e4 | A common gene variant that raises the risk of developing Alzheimer’s without making it certain. |
| Deterioro cognitivo leve | Thinking changes greater than normal aging but not yet severe enough to be called dementia. |
| Tomografía PET | An imaging test that can show amyloid or tau build-up directly in the brain. |
| Anti-amyloid antibody | A lab-made antibody drug, such as lecanemab or donanemab, that clears amyloid from the brain. |
| ARIA | Amyloid-related imaging abnormalities: temporary brain swelling or small bleeds sometimes seen with anti-amyloid drugs. |
Preguntas frecuentes
Is forgetting names and appointments always a sign of Alzheimer’s?
No. Occasionally forgetting a name or an appointment and remembering it later is a common part of normal aging. The memory changes seen in Alzheimer’s are persistent, worsen over time, and start to interfere with everyday tasks. If lapses are becoming more frequent or disruptive, it is worth discussing them with a doctor rather than assuming the worst.
Is Alzheimer’s disease hereditary?
In most cases it is not directly inherited. Genes such as APOE e4 can raise the risk, but many carriers never develop the disease, and many people who do develop it carry no known risk gene. Rare families carry mutations that cause early-onset Alzheimer’s, which can appear in a person’s forties or fifties, but these account for only a small fraction of cases.
¿Un análisis de sangre puede diagnosticar el Alzheimer?
Blood tests that measure p-tau217 are a major advance and are now supported in specialist settings for people who already have memory symptoms. They are not yet a standalone diagnosis and are not meant for screening healthy people. A doctor still combines the result with history, cognitive testing, and sometimes imaging before reaching a conclusion.
What is the difference between Alzheimer’s and dementia?
Dementia is the umbrella term for a serious decline in memory and thinking that disrupts daily life, and it has several possible causes. Alzheimer’s disease is the most common of those causes. In other words, a person has dementia as the set of symptoms and Alzheimer’s as the underlying disease driving them.
Can Alzheimer’s disease be prevented?
There is no guaranteed way to prevent it, but risk can be lowered. Managing blood pressure, blood sugar, and weight, staying active, protecting hearing and sleep, not smoking, and keeping mentally and socially engaged all help. Health authorities estimate that a substantial share of dementia cases could be prevented or delayed by addressing these factors over a lifetime.
What is the life expectancy after a diagnosis?
It varies widely and depends on age, general health, and the stage at diagnosis. Many people live for several years, and some for a decade or more. Support, treatment of other conditions, and good day-to-day care all influence both length and quality of life, so a single number cannot capture any one person’s outlook.
Fuentes
- National Institute on Aging (NIH) — Alzheimer’s Disease Fact Sheet, 2023 — nia.nih.gov
- Alzheimer’s Association — What Is Alzheimer’s Disease?, 2025 — alz.org
- Centers for Disease Control and Prevention — About Dementia, 2024 — cdc.gov
- MedlinePlus, National Library of Medicine — Alzheimer’s Disease, 2025 — medlineplus.gov
- U.S. Food and Drug Administration — FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval (Leqembi), 2023 — fda.gov
- U.S. Food and Drug Administration — FDA Approves Treatment for Adults With Alzheimer’s Disease (Kisunla), 2024 — fda.gov
- Palmqvist S, et al. — Biomarcadores en sangre para detectar la enfermedad de Alzheimer en atención primaria y secundaria — JAMA, 2024 — doi.org/10.1001/jama.2024.13855
- Ashton NJ, et al. — Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology — JAMA Neurology, 2024 — doi.org/10.1001/jamaneurol.2023.5319
- Palmqvist S, et al. — Plasma phospho-tau217 para el diagnóstico de la enfermedad de Alzheimer en atención primaria y secundaria mediante una plataforma totalmente automatizada — Nature Medicine, 2025 — doi.org/10.1038/s41591-025-03622-w
- Palmqvist S, et al. — Alzheimer’s Association clinical practice guideline on blood-based biomarkers in specialized care — Alzheimer’s & Dementia, 2025 — doi.org/10.1002/alz.70535
- ClinicalTrials.gov — Study to Confirm Safety and Efficacy of Lecanemab in Early Alzheimer’s Disease (Clarity AD), NCT03887455 — clinicaltrials.gov/study/NCT03887455
- ClinicalTrials.gov — A Study of Donanemab in Early Alzheimer’s Disease (TRAILBLAZER-ALZ 2), NCT04437511 — clinicaltrials.gov/study/NCT04437511
- ChEMBL, EMBL-EBI — Lecanemab (Leqembi), CHEMBL3833321 — ebi.ac.uk/chembl
- ChEMBL, EMBL-EBI — Donanemab (Kisunla), CHEMBL4297245 — ebi.ac.uk/chembl
Lecturas recomendadas
- Dementia: symptoms, causes, and types
- The new FDA-cleared Alzheimer’s blood test
- What the p-tau217 blood test predicts
- The TSH thyroid hormone test
- Vitamina B12 baja: síntomas, causas y tratamientos
Entiende tus resultados de laboratorio con AI DiagMe
Alzheimer’s disease cannot be confirmed from a single blood value, but the right lab work helps your doctor rule out treatable conditions that mimic memory problems, such as an underactive thyroid, a vitamin B12 or folate shortfall, or raised homocysteine. AI DiagMe interprets results like your TSH, vitamin B12, folate, and inflammation markers in clear language, so you understand what each number means before your appointment. It is built to help you understand your results, not to give a diagnosis, and it does not replace your doctor.
Obtén la lectura de tus resultados en minutos
